A Recent Clinical Trial on Wheat Oral Immunotherapy in Allergic Children

Overview of Wheat as a Crop

Bread wheat is one of the most cultivated crops globally, known for its high yields and adaptability to various climates. It is not only nutritious and flavorful but also serves as a staple ingredient in many foods, including pasta, bread, and pizza, as well as beverages like beer.

Wheat Allergy and Its Impact

Despite its benefits, wheat can trigger allergic reactions in certain individuals. The digestive system typically breaks down food into basic components, but in genetically predisposed people, wheat proteins can provoke an allergic response. Wheat allergies are more prevalent in children, with many outgrowing the condition by age 16, leading to lower rates in adults.

Common Symptoms of Wheat Allergy

Symptoms associated with a wheat allergy can include hives, asthma, abdominal pain, vomiting, hay fever, and dermatitis. Anaphylaxis represents a severe reaction that can occur rapidly after exposure to wheat, with symptoms such as hives, difficulty breathing, and fainting. Reactions can also occur through inhalation, affecting individuals who are consistently exposed to wheat products.

Current Management Strategies

Currently, the primary method for managing wheat allergies involves avoiding exposure and treating symptoms as they arise. Allergy immunotherapy is emerging as a promising treatment, designed to reduce a patient’s sensitivity to wheat through gradual exposure to the allergen.

Clinical Trial on Wheat Oral Immunotherapy

Study Objectives

A recent clinical trial aimed to investigate the efficacy and safety of vital wheat gluten oral immunotherapy among allergic patients. Vital wheat gluten, derived from wheat flour, is rich in protein, allowing participants to consume the necessary wheat protein without excessive food intake.

Study Design and Methodology

The trial involved 46 participants aged between four and 30, randomly assigned to two groups: one receiving oral immunotherapy (OIT group) and the other a placebo for comparison. Over one year, the OIT group received increasing doses of wheat protein, followed by a maintenance phase lasting another year. The sensitivity of participants to wheat was monitored at the one-year mark and again after the second year.

Results of the Study

The findings revealed that approximately 52.2% of participants in the OIT group exhibited decreased sensitivity to wheat after the first year, enabling them to consume the equivalent of one to two slices of bread without symptoms. In contrast, the placebo group showed no improvement. By the end of the second year, 30% of the OIT group had lost their sensitivity to wheat, able to eat a standard serving without adverse reactions. However, follow-up assessments indicated that only 13% remained non-sensitive two months after treatment cessation.

Safety and Side Effects

Regarding safety, the most frequently reported side effects during the first year of OIT treatment were respiratory and gastrointestinal symptoms, with a small number classified as severe. While the rate of symptoms decreased during the second year, 24% of participants discontinued treatment due to adverse reactions.

Limitations of the Study

One notable limitation of the study is the small participant pool, which may not adequately represent the broader population affected by wheat allergies. Additionally, the trial primarily included patients with severe wheat allergies, suggesting that including those with milder cases might enhance both efficacy and safety.

Future Directions for Wheat Oral Immunotherapy

To optimize wheat oral immunotherapy, adjustments in dosing and treatment duration may be necessary based on this study’s findings.

Conclusion

In summary, this clinical trial assessed the safety and efficacy of oral immunotherapy for wheat allergies. The gradual introduction of increasing doses of wheat protein over one year successfully reduced sensitivity in a significant number of patients. Although 30% of participants were able to consume wheat products without symptoms after an additional year of treatment, the sustainability of these effects appears less durable compared to other food immunotherapy studies. The results lay the groundwork for future enhancements in therapy protocols, potentially involving modifications to dosage and treatment duration.

References

Nowak-Węgrzyn, A., Wood, R. A., Nadeau, K. C., Pongracic, J. A., Henning, A. K., Lindblad, R. W., Beyer, K., & Sampson, H. A. (2018). Multicenter, randomized, double-blind, placebo-controlled clinical trial of vital wheat gluten oral immunotherapy. Journal of Allergy and Clinical Immunology.

Cianferoni, A. (2016). Wheat allergy: diagnosis and management. Journal of Asthma and Allergy, 9, 13–25.

Mount Sinai researchers find wheat oral immunotherapy to be therapeutic for allergic patients. https://www.eurekalert.org/pub_releases/2018-10/tmsh-ms103018.php

Baiu, I., & Melendez, E. (2018). Anaphylaxis in Children. JAMA, 319(9), 943.